Why are US fentanyl deaths falling? | DW News

Key Concepts

• Fentanyl: A highly potent synthetic opioid responsible for a significant portion of US overdose deaths.
• Precursor Chemicals: Raw chemical substances used in the illicit manufacturing of fentanyl.
• Xylazine: A veterinary tranquilizer often mixed with fentanyl, which reduces the frequency of opioid use but causes severe health complications like tissue necrosis and amputations.
• Harm Reduction: Public health strategies (e.g., drug testing strips, Naloxone) aimed at reducing the negative consequences of drug use.
• Strategic Leverage: The use of diplomatic and economic pressure to influence foreign government cooperation regarding drug supply chains.

---

1. The Evolution of the Fentanyl Crisis

The US opioid epidemic originated in the 1990s with prescription painkillers. By 2013, Chinese suppliers began shipping finished fentanyl directly to US consumers via postal services. Around 2015–2016, Mexican cartels (notably the Sinaloa Cartel and Cartel de Jalisco) entered the market, taking over wholesale distribution. By the peak of the crisis, fentanyl was responsible for approximately 110,000 overdose deaths annually (2023), affecting one in eight Americans.

2. Factors Behind the Decline in Overdose Deaths

Data shows a significant drop in overdose deaths starting in 2023, prior to the current administration's policies. Experts attribute this to four primary factors:

• Supply Chain Shifts: Following 2019 regulations, China shifted from exporting finished fentanyl to exporting precursor chemicals to Mexico.
• Cartel Behavior: There is anecdotal evidence that cartels may have reduced the potency of their product due to US law enforcement pressure.
• User Adaptation: The introduction of adulterants like Xylazine has altered usage patterns. While it causes severe morbidity, it reduces the frequency of fentanyl consumption, thereby lowering the immediate risk of fatal overdose.
• Public Health Initiatives: Expanded access to Naloxone (overdose reversal medication), mental health services, and improved insurance coverage for addiction treatment were critical in stabilizing the death rate.

3. Critique of Current Administration Tactics

Vanda Felbab-Brown of the Brookings Institution argues that the current administration’s "militarized" approach—including tariffs and the designation of fentanyl as a weapon of mass destruction—is counterproductive.

• Diplomatic Redundancy: The administration dismissed existing cooperation with China established in 2024. By imposing tariffs, they triggered retaliatory measures, only to eventually receive the same cooperation deliverables from China that were already negotiated by the previous administration.
• Dismantling Public Health: The administration has significantly reduced funding for harm reduction tools, such as drug testing strips, and created new obstacles to insurance-backed addiction treatment.
• The "Dangerous Experiment": Felbab-Brown characterizes the current policy shift as a "dangerous experiment," warning that by unwinding the very policies that helped lower death rates, the administration risks a resurgence in fatalities.

4. Data and Research Findings

• Seizure Discrepancies: Contrary to the argument that China "turned off" the supply of precursors in 2023, data shows Chinese precursor seizures were higher in 2020 (2,000+ tons) than in 2024 (approx. 1,400 tons), suggesting the decline in US deaths is not solely due to a sudden Chinese crackdown.
• Mortality Trends: Drug overdose deaths dropped by more than a third from their 2023 peak, marking the sharpest reversal in 15 years.

5. Notable Quotes

• "We are running a very dangerous experiment, which is, are we going to see drug overdose deaths going up?" — Vanda Felbab-Brown, Brookings Institution.
• "Even if they [death reductions] hold, 70,000 Americans dead is not an acceptable number." — Vanda Felbab-Brown.

---

Synthesis and Conclusion

The decline in US fentanyl-related deaths is a complex phenomenon driven by a combination of supply-side shifts, changes in drug composition (Xylazine), and, most importantly, expanded public health and harm reduction infrastructure. The current administration’s strategy of prioritizing aggressive tariffs and militarized enforcement over established diplomatic cooperation and public health funding is viewed by experts as a high-stakes gamble. By dismantling the support systems that contributed to the 2023–2024 decline, the administration may be jeopardizing the progress made in curbing the deadliest phase of the opioid epidemic.